KRAS and adenocarcinoma: Recently, CD274 (encoding PD-L1) blockade has been proved to be a promising KRAS-mutant adenocarcinoma treatment option.67 MYC-targeted therapies, similar to KRAS-targeted therapies, have proven to be a challenge to explore.